
Monday, December 23, 2024 11:36:27 PM
HUMBL STOCK PRICE FOR 2025
To forecast the stock price of Humbl Inc (HMBL) for the year 2025, we can analyze the available predictions and trends based on recent data. As of December 24, 2024, the current price of HMBL is approximately $0.0008 USD.
Current Price Analysis: The stock has been experiencing a downtrend since late December 2023, indicating some volatility in its performance. However, there are optimistic forecasts regarding its future value.
Forecast for 2025: According to various analyses, the average price target for HUMBL Inc in 2025 is projected to be around $0.2285 USD. This represents a significant increase from the current price, suggesting an upside potential of approximately 32,547%.
Price Range Predictions: The forecasts also provide a range for HMBL’s price in 2025:
The high prediction is about $0.3949 USD.
The low estimate is around $0.0622 USD.

Recent HMBL News
- Form SEC STAFF ACTION - SEC Staff Action: ORDER • Edgar (US Regulatory) • 07/09/2025 03:00:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/05/2025 09:30:06 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 05/09/2025 09:31:33 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 04/30/2025 08:47:31 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 04/18/2025 08:05:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2025 08:34:05 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2025 03:30:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/18/2025 08:10:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2025 10:13:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2025 10:27:27 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 12/26/2024 09:05:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2024 07:25:49 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/20/2024 02:43:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2024 09:05:16 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 12/11/2024 10:21:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/03/2024 03:42:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/19/2024 09:00:38 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2024 11:14:27 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2024 04:10:18 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 09/11/2024 08:35:17 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 08/30/2024 08:40:44 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2024 08:53:54 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2024 08:16:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 08:05:13 PM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM